Johnson and Johnson 2009 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2009 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

JOHNSON & JOHNSON 2009 ANNUAL REPORT 11
cancer, gained in the acquisition of Cougar
Biotechnology, Inc. by Johnson & Johnson
in July .
“In our pivotal trials with abiraterone
acetate, we’ve used ® as
an indicator of drug eectiveness,” says
Bill Hait, M.D., Ph.D., Global Therapeutic
Head of Oncology & Hematology,
Centocor Research & Development, Inc.
“Through collaborations, we’re
developing molecular characterizations
of cancer cells to begin to define
predictive biomarkers that may help
to identify which patients will do best
on the drug.”
The ability to understand quickly
whether a medicine is right or most
eective for a given patient is a primary
objective in the pursuit of personalized
medicine. “Partnering with the drug
biomarkers group in the pharmaceutical
organization gives us a real opportunity to
potentially expand the capability of
®
to predict and monitor
therapeutic responses,” says Mark Carle
Connelly, Ph.D., Director of Cellular
Research, Veridex, LLC. “The vision is to
ultimately transform the treatment
of cancer.”
Jesica delivered a healthy baby boy,
Gunner. She completed her cancer
treatment and is in remission.
But looking back, Jesica felt her
individuality was lost in a cookbook
approach to her cancer treatment.
She says, “When I talked to my doctors,
they told me ‘Everyone is dierent,’
and I said, ‘Exactly.’”
Jesica, a teacher in Castle Rock, Colo., is an outspoken
breast cancer survivor. Results from a ® Circulating Tumor Cell test during
Jesica’s treatment fueled her hope of beating cancer as well as the support of her family,
friends and students. The girls sported pink hairspray, while the boys shaved their
hair when Jesica lost hers.